SAN DIEGO--(BUSINESS WIRE)--Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) announced today an update on its progress in developing novel small molecule compounds with cellular and tissue regenerative properties that could play a beneficial therapeutic role in radiation- and chemotherapy-induced bone marrow suppression. As reported at the 35th Annual Scientific Meeting of the International Society for Experimental Hematology (“ISEH”) held September 27-30, 2006, in Minneapolis, Minnesota, and in the November 2006 issue of International Immunopharmacology (available at www.elsevier.com), Hollis-Eden is advancing development of first- and second-generation compounds that demonstrate the ability to maintain bone marrow function and stimulate multilineage hematopoiesis after radiation- or chemotherapy-induced toxicity.
